|
業務類別
|
Biotechnology |
|
業務概覽
|
Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune responseagainst tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms. |
| 公司地址
| 2625 Townsgate Road, Suite 230, Westlake Village, CA, USA, 91361 |
| 電話號碼
| +1 805 267-9889 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.genelux.com |
| 員工數量
| 26 |
| Mr. Thomas Zindrick, J.D. |
Chairman of the Board, President and Chief Executive Officer |
美元 613.00K |
29/04/2026 |
| Mr. Eric Groen |
General Counsel, Corporate Secretary, Chief Compliance Officer and Head of Business Development |
-- |
29/04/2026 |
| Dr. Jason Litten, M.D. |
Chief Medical Officer |
-- |
02/01/2026 |
| Mr. Matthew Pulisic |
Chief Financial Officer and Principal Accounting Officer |
美元 406.74K |
29/04/2026 |
| Dr. Tony Yu, PhD |
Senior Vice President, Clinical Development |
-- |
29/04/2026 |
| Dr. Joseph Cappello, PhD |
Chief Technical Officer |
美元 390.00K |
29/04/2026 |
| Mr. Ralph Smalling |
Head, Regulatory |
-- |
29/04/2026 |
|
|
| Ms. Mary Mirabelli |
Independent Director |
29/04/2026 |
| Mr. Thomas Zindrick, J.D. |
Chairman of the Board, President and Chief Executive Officer |
29/04/2026 |
| Mr. James L. Tyree |
Lead Independent Director |
29/04/2026 |
| Dr. John Thomas, PhD |
Independent Director |
29/04/2026 |
| Mr. John W. Smither |
Independent Director |
29/04/2026 |
|
|
|
|
